Loading
A phase 2 trial of Olaparib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) is a phase 2 interventional study registered as NCT03742895 by Merck Sharp & Dohme LLC, with 329 participants enrolled, started 2018-12-12 and due to reach its primary completion in 2025-08-12. Interventions recorded: Olaparib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
329 enrolled.
95% CI 9.2 to 25.8; Figures from the ClinicalTrials.gov results section (first posted 2026-08-14), not from a publication · 95% CI 3.9 to 16.8 · 95% CI 4.5 to 14.5 · 95% CI 3.7 to 71.0
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Cohorts 1, 2, 3: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or Prostate Cancer Working Group (PCWG)-Modified RECIST 1.1primary | Cohort 1: BRCA1/2 Mutated | 86 | 16.3% | - | - | link |
| Cohort 2: HRD+, HRR Non-mutated | 90 | 8.9% | ||||
| Cohort 2: HRRm, BRCA1/2 Non-mutated | 140 | 8.6% | ||||
| Cohort 3: sBRCAm Breast Cancer | 7 | 28.6% |
Shares PARP inhibitors, Olaparib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib, Merck & Co. (MSD), AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.